Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | SDHB | P21912 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561619 | 0.86 | KDM4E (0.68) | SMN1; SMN2ALDH1A1L3MBTL1HSD17B10KDM4E | |
| SCHEMBL3557132 | 0.86 | KDM4E (0.71) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3566819 | 0.85 | CYP3A4 (0.52) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3567866 | 0.84 | KDM4E (0.55) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3559691 | 0.83 | XDH (0.49) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL18527435 | 0.83 | HSD17B10 (0.71) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL782567 | 0.80 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3559923 | 0.80 | KDM4E (0.51) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3557053 | 0.79 | KMO (0.53) | SMN1; SMN2ALDH1A1HSD17B10KDM4EMAPK1 | |
| SCHEMBL30230259 | 0.79 | KDM4E (0.69) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2020-11-05 | — | — | US | disclosed |
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2020-11-05 | — | — | US | disclosed |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190016715-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | disclosed |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3154954-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford-Burnham Medical Research Institute (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015191630-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015191630-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-17 | — | — | WO | disclosed |
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| CN-100341862-C | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORP (JP) | 2007-10-10 | — | — | CN | disclosed |
| CN-1606549-A | Thiazolidine derivative and medical application thereof | MITSUBISHI PHARMA CORP (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | MEN1 2740/4885KMT2A 942/4885SMN1; SMN2 1357/4885 |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | MEN1 3295/4885KMT2A 1595/4885SMN1; SMN2 3494/4885 |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | DPP4, DPP7, DPP3 | MEN1 2196/4885KMT2A 1883/4885SMN1; SMN2 2677/4885 |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | GRM3, GRM2, GRM1 | MEN1 2740/4885KMT2A 942/4885SMN1; SMN2 1357/4885 |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | MEN1 2740/4885KMT2A 942/4885SMN1; SMN2 1357/4885 |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | MEN1 2740/4885KMT2A 942/4885SMN1; SMN2 1357/4885 |
| US-20190016715-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | MEN1 2740/4885KMT2A 942/4885SMN1; SMN2 1357/4885 |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | MEN1 2740/4885KMT2A 942/4885SMN1; SMN2 1357/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | MEN1 2193/4885KMT2A 1325/4885SMN1; SMN2 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.